Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 07, 2023

SELL
$11.12 - $22.2 $117,927 - $235,431
-10,605 Reduced 4.34%
233,584 $2.68 Million
Q1 2023

May 09, 2023

SELL
$18.7 - $23.07 $86,375 - $106,560
-4,619 Reduced 1.86%
244,189 $4.92 Million
Q4 2022

Feb 09, 2023

SELL
$18.12 - $27.32 $99,714 - $150,341
-5,503 Reduced 2.16%
248,808 $5.64 Million
Q3 2022

Nov 09, 2022

BUY
$16.98 - $25.54 $451,786 - $679,542
26,607 Added 11.68%
254,311 $4.77 Million
Q2 2022

Aug 10, 2022

SELL
$13.15 - $20.45 $201,221 - $312,925
-15,302 Reduced 6.3%
227,704 $4.24 Million
Q1 2022

May 09, 2022

SELL
$14.54 - $21.5 $35,739 - $52,847
-2,458 Reduced 1.0%
243,006 $4.39 Million
Q4 2021

Feb 09, 2022

SELL
$20.24 - $36.01 $175,035 - $311,414
-8,648 Reduced 3.4%
245,464 $5.09 Million
Q3 2021

Nov 09, 2021

BUY
$26.01 - $38.22 $6.34 Million - $9.32 Million
243,843 Added 2374.55%
254,112 $8.13 Million
Q2 2021

Aug 10, 2021

BUY
$29.97 - $37.17 $11,718 - $14,533
391 Added 3.96%
10,269 $316,000
Q1 2021

May 10, 2021

BUY
$29.24 - $42.03 $20,351 - $29,252
696 Added 7.58%
9,878 $333,000
Q4 2020

Feb 08, 2021

BUY
$35.35 - $50.67 $5,938 - $8,512
168 Added 1.86%
9,182 $332,000
Q3 2020

Nov 06, 2020

SELL
$35.98 - $47.66 $15,831 - $20,970
-440 Reduced 4.65%
9,014 $331,000
Q2 2020

Aug 05, 2020

BUY
$45.06 - $67.74 $162,125 - $243,728
3,598 Added 61.44%
9,454 $426,000
Q1 2020

May 12, 2020

BUY
$40.01 - $73.97 $13,203 - $24,410
330 Added 5.97%
5,856 $278,000
Q4 2019

Feb 05, 2020

SELL
$37.13 - $74.62 $11,584 - $23,281
-312 Reduced 5.34%
5,526 $396,000
Q3 2019

Nov 13, 2019

BUY
$39.36 - $76.8 $2,243 - $4,377
57 Added 0.99%
5,838 $230,000
Q2 2019

Aug 12, 2019

SELL
$52.76 - $82.19 $1,055 - $1,643
-20 Reduced 0.34%
5,781 $452,000
Q1 2019

May 10, 2019

BUY
$27.39 - $68.41 $158,889 - $396,846
5,801 New
5,801 $346,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $740M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.